The ROE as of December 2024 (TTM) for Resverlogix Corp. (RVXCF) is 12.20%

According to Resverlogix Corp.’s latest financial reports and current stock price. The company's current ROE is 12.20%. This represents a change of 221.18% compared to the average of 3.80% of the last 4 quarters.

Resverlogix Corp. (RVXCF) Historical ROE (quarterly & annually)

How has RVXCF ROE performed in the past?

The mean historical ROE of Resverlogix Corp. over the last ten years is 7.33%. The current 12.20% ROE has changed 66.41% with respect to the historical average. Over the past ten years (40 quarters), RVXCF's ROE was at its highest in in the July 2018 quarter at 37.24%. The ROE was at its lowest in in the October 2019 quarter at -122.63%.

Resverlogix Corp. (RVXCF) ROE by Quarter and Year

Discovering the peaks and valleys of Resverlogix Corp. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Resverlogix Corp. (RVXCF) Average ROE

How has RVXCF ROE performed in the past?

The current ROE of Resverlogix Corp. (RVXCF) is less than than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

Resverlogix Corp. (RVXCF) ROE vs. Peers

How is RVXCF’s ROE compared to its peers?

Resverlogix Corp.’s ROE is greater than Cellectis S.A. (-75.49%), greater than Biotron Limited (-423.05%), greater than Small Pharma Inc. (-78.43%), greater than Covalon Technologies Ltd. (-4.23%), greater than Bioasis Technologies Inc. (0%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than Biohaven Pharmaceutical Holding Company Ltd. (-225.12%), less than ImmunityBio, Inc. (86.39%), greater than Cadrenal Therapeutics, Inc. Common Stock (-142.95%), less than Foghorn Therapeutics Inc. (167.93%), less than Comera Life Sciences Holdings, Inc. (67.46%), less than Coya Therapeutics, Inc. (0%), greater than NewAmsterdam Pharma Company N.V. (-31.59%), greater than Centessa Pharmaceuticals plc (-53.79%), greater than Eliem Therapeutics, Inc. (-52.22%), less than Inhibrx Biosciences, Inc. (0%), less than Merrimack Pharmaceuticals, Inc. (1.45%), greater than Celcuity Inc. (-35.28%), greater than Enliven Therapeutics, Inc. (-62.66%), greater than null (-29.46%),

Build a custom stock screener for Resverlogix Corp. (RVXCF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Resverlogix Corp. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Resverlogix Corp. (RVXCF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Resverlogix Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.